A multi-drug phosphoproteomic diagnostic and cancer treatment selection algorithm for precision medicine

用于精准医疗的多药磷酸蛋白质组学诊断和癌症治疗选择算法

• 批准号: 10054602
• 金额: $ 88.89万
• 依托单位: KINOMICA LIMITED
• 依托单位国家: 英国
• 项目类别: Investment Accelerator
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10054602
• 关键词: multi; drug; phosphoproteomic; diagnostic; cancer

Decades of intensive research has produced a wealth of anticancer treatments. A problem for the success of these therapies is that not all patients will respond to treatments in the same way, so some may respond well to a treatment while others respond poorly to that same treatment. It is difficult therefore to know, or predict, which patients will be responders or non-responders to the growing number of available drugs.This project addresses this clinical, societal and economic challenge. We propose the development of a new type of diagnostic test based on predictive protein activity signatures, that will be able to distinguish how well a patient is likely to respond to different anticancer drugs.While several competing technologies in the field of precision medicine diagnostics now exist, Kinomica's solution has a competitive advantage because it is based on measuring the activity, rather than just mutations or abundance levels, of proteins that drive cancer growth and are the targets of drugs designed to block cancer growth.The project builds from previous work, in part funded by Innovate UK, where we demonstrated that our technology predicted responses to a treatment (midostaurin plus chemotherapy) for an aggressive form of leukaemia, with much greater accuracy than when using the currently approved diagnostic tests (based on gene mutation analysis).Successful completion of the project will provide a test that can select the best drug for each leukaemia patient from the growing number of available treatments, thus improving response rates, survival times and quality of life. Furthermore, this work will lead to new and improved methods, inventions and improved diagnostics to help clinicians treat their cancer patients effectively. The outputs will be made public in high-impact publications and presentations in conferences. Importantly, the project will deliver a novel diagnostic technology that could be applied to help more effectively treat other cancers beyond leukaemia.This project will change our R&D activities by unlocking additional private funding, and opens the prospect of creating a centre of excellence in precision medicine diagnostics in the North West of England, with the positive consequent implications for economic development in the area.

几十年的深入研究已经产生了丰富的抗癌治疗方法。这些疗法成功的一个问题是，并非所有患者都会以相同的方式对治疗作出反应，因此一些患者可能对治疗反应良好，而另一些患者对相同的治疗反应不佳。因此，很难知道或预测哪些患者将对越来越多的可用药物有反应或无反应。本项目解决了这一临床、社会和经济挑战。我们建议开发一种基于预测性蛋白质活性特征的新型诊断测试，该测试将能够区分患者对不同抗癌药物的反应程度。虽然目前在精确医学诊断领域存在几种相互竞争的技术，但Kinomica的解决方案具有竞争优势，因为它基于测量活性，而不仅仅是突变或丰度水平，该项目建立在以前的工作基础上，部分由Innovate UK资助，在那里我们证明了我们的技术可以预测对治疗的反应。（米多替林加化疗）治疗侵袭性白血病，其准确性比使用当前批准的诊断测试时高得多该项目的成功完成将提供一种测试，可以从越来越多的现有治疗方法中为每个白血病患者选择最佳药物，从而提高反应率，生存时间和生活质量。此外，这项工作将导致新的和改进的方法，发明和改进的诊断，以帮助临床医生有效地治疗他们的癌症患者。这些产出将在影响力大的出版物和在会议上的介绍中公布。重要的是，该项目将提供一种新的诊断技术，可用于帮助更有效地治疗白血病以外的其他癌症。该项目将通过释放额外的私人资金来改变我们的研发活动，并开辟了在英格兰西北部创建精准医学诊断卓越中心的前景，对该地区的经济发展产生积极影响。